Overview / Abstract: |
STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this activity, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiwess, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC. TARGET AUDIENCE Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: -Evaluate the implications of hormone receptor and HER2 expression status for prognostication and treatment selection in TNBC |
Expiration |
Aug 01, 2024 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1.25 CME | 1.25 NCPD | MOC | ILNA |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Ira J. Bleiweiss, MD Sara M. Tolaney, MD, MPH |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Gilead Sciences, Inc. |
Keywords / Search Terms |
i3 Health i3 Health, breast cancer, breast cancer therapies, cme, continuing medical education, managing side effects, ncpd, oncology, oncology nurse, oncology nursing, oncology nursing society, oncology physician, supportive care, toxicity breast cancer, Free CE, CME Free CE CME |